Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yu, Yue

doi:10.1007/s11684-013-0272-4

Cited by 31 publications

(23 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of these facts point to the value of molecular classifications as nonsubjective adjuvant methods. These methods include digital nuclear imaging, mutation analysis, mRNA expression values and various other molecular methods, either alone or in combination …”

Section: Introductionmentioning

confidence: 99%

Genome‐wide copy number variation pattern analysis and a classification signature for non‐small cell lung cancer

Qiu

Gazdar

et al. 2017

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

The accurate classification of non-small cell lung carcinoma (NSCLC) into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is essential for both clinical practice and lung cancer research. Although the standard WHO diagnosis of NSCLC on biopsy material is rapid and economic, more than 13% of NSCLC tumors in the USA are not further classified. The purpose of this study was to analyze the genome-wide pattern differences in copy number variations (CNVs) and to develop a CNV signature as an adjunct test for the routine histopathologic classification of NSCLCs. We investigated the genome-wide CNV differences between these two tumor types using three independent patient datasets. Approximately half of the genes examined exhibited significant differences between LUAD and LUSC tumors and the corresponding non-malignant tissues. A new classifier was developed to identify signature genes out of 20 000 genes. Thirty-three genes were identified as a CNV signature of NSCLC. Using only their CNV values, the classification model separated the LUADs from the LUSCs with an accuracy of 0.88 and 0.84, respectively, in the training and validation datasets. The same signature also classified NSCLC tumors from their corresponding non-malignant samples with an accuracy of 0.96 and 0.98, respectively. We also compared the CNV patterns of NSCLC tumors with those of histologically similar tumors arising at other sites, such as the breast, head, and neck, and four additional tumors. Of greater importance, the significant differences between these tumors may offer the possibility of identifying the origin of tumors whose origin is unknown.

show abstract

Section: Introductionmentioning

confidence: 99%

Genome‐wide copy number variation pattern analysis and a classification signature for non‐small cell lung cancer

Qiu

Gazdar

et al. 2017

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

“…Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer, with 5 year-survival of less than 20% [2]. Early diagnosis represents one of the most effective strategies in improving survival and prognosis of lung cancer patients [3–5]. Therefore, it is important to understand the molecular mechanism in NSCLC tumorigenesis in order to identify biomarkers for early diagnosis and management of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway

Tian

Jin

et al. 2017

Mol Cancer

View full text Add to dashboard Cite

BackgroundThe telomerase/telomere interacting protein PinX1 has been suggested as a tumor suppressor. However, the clinical and biological significance of PinX1 in human non-small cell lung cancer (NSCLC) is unclear.MethodsPinX1 gene/expression pattern and its association with NSCLC patient survival were analyzed in cBioportal Web resource and two cohorts of NSCLC samples. A series of in vivo and in vitro assays were performed to elucidate the function of PinX1 on NSCLC cells proliferation and underlying mechanisms.ResultsMore frequency of gene PinX1 homozygous deletion and heterozygote deficiency was first retrieved from cBioportal Web resource. Low expression of PinX1 correlated with smoking condition, histological type, T stage, N stage, M stage and TNM stage, and was an independent predictor for overall survival in a learning cohort (n = 93) and a validation cohort (n = 51) of NSCLC patients. Furthermore, knockdown of PinX1 dramatically accelerated NSCLC cell proliferation and G1/S transition, whereas ectopic overexpression of PinX1 substantially inhibited cell viability and cell cycle transition in vitro and in vivo. p15/cyclin D1 pathway and BMP5 might contribute to PinX1-associated cell proliferation and cell cycle transition.ConclusionThe cost-effective expression of PinX1 could constitute a novel molecular predictor/marker for NSCLC management.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-017-0637-4) contains supplementary material, which is available to authorized users.

show abstract

“…In the era of precision medicine, the specialty of oncology has led efforts to identify distinct tumor subtypes for several cancers (eg, breast cancer and lung cancer) based on tumor‐specific characteristics and molecular profiles. The goal of these efforts is to develop mechanistically based cancer treatments .…”

Section: Introductionmentioning

confidence: 99%

Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

Miaskowski

Cooper

Melisko

et al. 2014

Cancer

102

104

View full text Add to dashboard Cite

Background A large amount of inter-individual variability exists in the occurrence of symptoms in patients on chemotherapy (CTX). The purposes of this study, in a sample of oncology outpatients who were receiving CTX (n=582), were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in QOL outcomes were evaluated. Methods Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale prior to their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. Results Three distinct subgroups of patients were identified (i.e., 36.1% in Low class; 50.0% in Moderate class, 13.9% in All High class). Patients in the All High class were significantly younger, more likely to be female and Non-white, had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. Conclusions Findings from this study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high risk patients experience significant decrements in QOL.

show abstract

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Cited by 31 publications

References 80 publications

Genome‐wide copy number variation pattern analysis and a classification signature for non‐small cell lung cancer

Genome‐wide copy number variation pattern analysis and a classification signature for non‐small cell lung cancer

The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway

Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

Contact Info

Product

Resources

About